|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although follow-up for the vast majority of these children does not yet extend beyond young adulthood, a slight increase in cancers in those with long-standing excess GH secretion (as seen in patients with acromegaly) and no overall increase in cancer with insulin treatment, have been observed.
|
20956999 |
2011 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
The osteoblast-to-insulin axis seems to act paradoxically in patients with increased growth hormone (acromegaly) and during bone repair.
|
21519236 |
2011 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results indicate that increased MN frequency in the lymphocytes of patients with acromegaly may reflect genomic instability and this increased MN frequency may be associated with elevated levels of circulating growth hormone and IGF-1.
|
21550080 |
2011 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
We explored the oxidative stress levels in the serum and tissues of GH-transgenic rats as an animal model for acromegaly.
|
22370764 |
2012 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia in acromegaly with severe visceromegaly and divergence between growth hormone and insulin-like growth factor-1 concentrations during the follow-up: causal or casual association?
|
22364960 |
2012 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is a syndrome that results when the pituitary gland produces excess growth hormone after epiphyseal closure at puberty.
|
22200909 |
2012 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Patients were assessed for recurrence of acromegaly with GH levels (random or nadir during an oGTT).
|
23648743 |
2013 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Increased secretion of growth hormone leads to gigantism in children and acromegaly in adults; the genetic causes of gigantism and acromegaly are poorly understood.
|
25470569 |
2014 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
An uncontrolled hyperactive GH-IGF-1 axis may play a dominant role in the development of PTC rather than the BRAFV600E mutation in patients with acromegaly.
|
25329702 |
2014 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The authors sought to comprehensively examine clinical and radiological correlates of growth hormone (GH)-secreting pituitary adenomas with regard to several commonly used immunocytochemical techniques in patients undergoing transsphenoidal surgery for acromegaly.
|
25238988 |
2014 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
To study the effect of chronic excess growth hormone on adipose tissue, we performed RNA sequencing in adipose tissue biopsies from patients with acromegaly (n = 7) or non-functioning pituitary adenomas (n = 11).
|
26087292 |
2015 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pituitary somatotroph adenomas result in dysregulated growth hormone (GH) hypersecretion and acromegaly; however, regulatory mechanisms that promote GH hypersecretion remain elusive.
|
25774503 |
2015 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Defects in the axis' activity during childhood result in growth abnormalities, while increased secretion of GH from the pituitary results in acromegaly.
|
27125739 |
2016 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A phase III trial of oral octreotide capsules demonstrated that this treatment can safely sustain suppressed levels of GH and IGF-1 and reduce the severity of symptoms in patients with acromegaly previously controlled by injectable SRL therapy, with the added benefit of no injection-site reactions.
|
26610414 |
2016 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Growth hormone (GH) excess in acromegaly is associated with increased precancerous colon polyps and soft tissue adenomas, whereas short-stature humans harboring an inactivating GH receptor mutation do not develop cancer.
|
27226307 |
2016 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
A low secretory activity of these tumours might explain the normal plasma values for GH and insulin-like growth factor 1 (IGF1) and the absence of clinical signs of acromegaly.
|
27913611 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is a rare disease generally brought about by a benign tumour in the pituitary and characterized by growth hormone (GH) and insulin-like growth factor 1 (IGF-1) excess.
|
28808855 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, IGF1, but not GH, has pro-inflammatory effects, probably via the MAPK signalling pathway and might be involved in the pathogenesis of atherosclerosis in acromegaly.
|
28611056 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Direct mitogenic properties of GH-IGF-1 axis on bone marrow progenitor cells may very rarely lead to erythroid hyperplasia and subsequent polycythaemia, reversible with successful therapy of acromegaly.
|
29222208 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is characterized by growth hormone (GH) and insulinlike growth factor-1 (IGF-1) hypersecretion, and GH and IGF-1 play important roles in regulating body composition and glucose homeostasis.
|
28945897 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data indicates that tissue-level properties of cortical bone are significantly altered in patients with controlled acromegaly after reversal of long-term exposure to pathologically high GH and IGF-1 levels.
|
28077497 |
2017 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Endocrine GH and IGF-1 were strongly upregulated without causing acromegaly.
|
28881863 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is a clinical syndrome caused by the excessive production of growth hormone.
|
26966026 |
2017 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Computed tomography airway lumen volumetry in patients with acromegaly: Association with growth hormone levels and lung function.
|
28217888 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Management of acromegaly is particularly challenging in cases where discordant information is obtained from measurement of GH concentrations following oral glucose load and from measurement of IGF-I.
|
28168377 |
2017 |